Your browser doesn't support javascript.
loading
Bcl-2 pathway inhibition in solid tumors: a review of clinical trials.
Ploumaki, Ioanna; Triantafyllou, Efthymios; Koumprentziotis, Ioannis-Alexios; Karampinos, Konstantinos; Drougkas, Konstantinos; Karavolias, Ioannis; Trontzas, Ioannis; Kotteas, Elias A.
Afiliação
  • Ploumaki I; Oncology Unit, 3rd Department of Medicine, 'Sotiria' General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
  • Triantafyllou E; Oncology Unit, 3rd Department of Medicine, 'Sotiria' General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
  • Koumprentziotis IA; Oncology Unit, 3rd Department of Medicine, 'Sotiria' General Hospital, National and Kapodistrian University of Athens, Athens, Greece. giannhskmpr@gmail.com.
  • Karampinos K; Oncology Unit, 3rd Department of Medicine, 'Sotiria' General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
  • Drougkas K; Oncology Unit, 3rd Department of Medicine, 'Sotiria' General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
  • Karavolias I; Oncology Unit, 3rd Department of Medicine, 'Sotiria' General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
  • Trontzas I; Oncology Unit, 3rd Department of Medicine, 'Sotiria' General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
  • Kotteas EA; Oncology Unit, 3rd Department of Medicine, 'Sotiria' General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Clin Transl Oncol ; 25(6): 1554-1578, 2023 Jun.
Article em En | MEDLINE | ID: mdl-36639602
Due to their key role in the pathogenesis of cancer through the regulation of apoptosis, the B-cell leukemia/lymphoma-2 (BCL-2) family proteins have been an attractive target for cancer therapy for the past decades. Throughout the years, many Bcl-2 family inhibitors have been developed, with Venetoclax being now successfully used in treating hematological malignancies. Although their effectiveness in the treatment of solid tumors is yet to be established, some preclinical evidence indicates their possible clinical application. This review aims to summarize current data from completed clinical trials that used Bcl-2 protein family inhibitors as monotherapy or in combination with other agents for the treatment of solid malignancies. We managed to include clinical trials of various phases which analyze the pharmacokinetics and pharmacodynamics of the drugs, as well as the effectiveness and adverse effects. Active and recruiting clinical trials are also briefly presented and future prospects and challenges are discussed.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Linfocítica Crônica de Células B / Neoplasias Hematológicas / Antineoplásicos Limite: Humans Idioma: En Revista: Clin Transl Oncol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Grécia País de publicação: Itália
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Linfocítica Crônica de Células B / Neoplasias Hematológicas / Antineoplásicos Limite: Humans Idioma: En Revista: Clin Transl Oncol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Grécia País de publicação: Itália